A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)

• Status: Completed
• Trial end date: 2006-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the efficacy and safety of an MK 0974 for migraine headache and to identify an appropriate dose range for further study.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Rizatriptan

Criteria

Inclusion Criteria:

• Patient has at least 1 year history of migraine (with or without aura)

• Females of childbearing years must use acceptable contraception throughout trial

• Patient is in general good health based on screening assessment

Exclusion Criteria:

• Patient is pregnant/breast-feeding (or is a female expecting to conceive during the study period)

• Patient has heart disease, uncontrolled hypertension (high blood pressure), uncontrolled diabetes or other significant disease

• Patient has major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other then migraine)

• Patient has a history of gastric or small intestinal surgery or has a disease that causes malabsorption

• Patient has a history of cancer within the last 5 years